# Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy

> **NCT04571216** · PHASE2 · COMPLETED · sponsor: **NFL Biosciences SAS** · enrollment: 318 (actual)

## Conditions studied

- Smoking Cessation
- Nicotine Dependence

## Interventions

- **DRUG:** NFL-101 dose 1
- **DRUG:** NFL-101 dose 2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04571216
- **Lead sponsor:** NFL Biosciences SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-12
- **Primary completion:** 2024-04-12
- **Final completion:** 2024-04-12
- **Target enrollment:** 318 (ACTUAL)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571216, "Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04571216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*